The United States Food and Drug Administration (FDA) recently revised its warning of a correlation between breast implants and the development of anaplastic large cell lymphoma (ALCL), a rare form of non-Hodgkin lymphoma. ALCL is not a breast cancer, its a cancer that originates in the lymphatic system and constitutes only one percent of all non-Hodgkin lymphoma cases. In 2011 the FDA identified a "possible association" but subsequently learned that most cases of breast implant associated ALCL reported "in the literature describe individuals who have had textured implants". 

Usually ALCL is found in the scar tissue and fluid by the implant but can also spread throughout the body. The FDA observed from recent published studies that ALCL "has been indentified in patients undergoing implant revision operations for late onset, persistent seroma (fluid collection around the implant)." Treatment involves the removal of the implant and the capsule around the implant, and sometimes chemotherapy and radiation.